GlassScriptPhysician profile
Garland Lee
NPI 1124456561
$10,341.60
in general payments reported to CMS, 2019-2025
32 companies · $1,577 in 2025
The $1,577 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,341 · 2022: $1,815 · 2023: $1,958 · 2024: $2,652 · 2025: $1,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,896 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,896.16 |
| Education | $289.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,744.56 | 2021-2025 | |
| Janssen Biotech, INC. | $1,492.68 | 2021-2025 | Tremfya |
| Pfizer INC. | $779.30 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $656.52 | 2021-2025 | |
| Dermavant Sciences, INC. | $638.43 | 2022-2024 | Vtama |
| Amgen INC. | $607.58 | 2021-2023 | Otezla |
| E.R. Squibb & Sons, L.L.C. | $551.78 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $499.65 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Arcutis Biotherapeutics, INC. | $463.39 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $457.44 | 2023-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $423.97 | 2021-2025 | |
| Genzyme Corporation | $359.85 | 2021-2024 | |
| Lilly USA, LLC | $266.96 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Almirall LLC | $179.26 | 2021-2024 | Seysara, Klisyri |
| Incyte Corporation | $158.68 | 2021-2024 | Opzelura |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $122.11 | 2021-2022 | |
| Organon LLC | $117.11 | 2025 | Vtama |
| Ucb, INC. | $115.38 | 2022-2024 | Bimzelx |
| Journey Medical Corporation | $113.22 | 2022-2025 | |
| Merz North America, INC. | $109.14 | 2021-2023 | Xeomin |
| Janssen Scientific Affairs, LLC | $92.00 | 2024 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $80.83 | 2021-2025 | Cabtreo |
| Strata Skin Sciences, INC. | $69.73 | 2023-2024 | Xtrac |
| Cipher Pharmaceuticals US LLC | $48.84 | 2025 | Natroba, Spinosad |
| Sun Pharmaceutical Industries INC. | $36.89 | 2021-2023 | Winlevi, Absorica Ld |
| Solta Medical, A Division of Bausch Health US, LLC | $35.40 | 2024-2025 | Clear & Brilliant |
| Verrica Pharmaceuticals INC. | $29.70 | 2025 | Ycanth |
| Dermira, INC. | $29.60 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.46 | 2021 | |
| Botanix Sb INC | $14.03 | 2025 | Sofdra |
| Mission Pharmacal Company | $13.62 | 2021 | |
| Vyne Pharmaceuticals INC. | $12.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garland Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.